Abstract
Larotrectinib and entrectinib are highly selective, potent tropomyosin receptor kinase
fusion inhibitors. It is U.S. Food and Drug Administration approved for the treatment
of adult and pediatric advanced solid tumors with neurotrophic tropomyosin receptor
kinase fusion genes who are refractory to standard systemic therapy. The response
rate was ~80% and was rapid and durable. The median progression-free survival was
28 months. The side effects include anemia, weight gain, hepatotoxicity, and neuropsychiatric
manifestations. Phase 3, randomized controlled trials are warranted to assess survival
benefit.
Keywords
larotrectinib - NTRK inhibitor - tumor agnostic therapy
